
Grail’s Galleri Cancer Test Faces Landmark FDA Review After Mixed Clinical Results
Grail’s ambitious effort to transform cancer screening is approaching a pivotal regulatory moment. The U.S. Food and Drug Administration has scheduled an advisory committee meeting for September 23, 2026,












